Respiratory Syncytial Virus (RSV) is a common respiratory virus that can cause mild cold-like symptoms, particularly in adults and older children. However, RSV can lead to severe respiratory infections, especially in infants, older adults, and individuals with weakened immune systems. RSV primarily spreads through respiratory droplets and can cause infections ranging from bronchiolitis to pneumonia. The virus is a leading cause of respiratory illness in young children and is particularly prevalent during the fall and winter months. Symptoms of RSV infection include cough, runny nose, fever, and difficulty breathing. Severe cases may require hospitalization, especially in infants. Preventive measures include frequent handwashing, avoiding close contact with sick individuals, and ensuring proper hygiene practices. There is ongoing research into developing vaccines and antiviral treatments for RSV. Given the impact of RSV, particularly on vulnerable populations, public health efforts focus on raising awareness, early diagnosis, and implementing preventive measures to reduce the burden of RSV-related illnesses.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom